Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Predictive Impact of Prognostic Nutritional Index on Pembrolizumab for Metastatic Urothelial Carcinoma Resistant to Platinum-based Chemotherapy

YUDAI ISHIYAMA, TSUNENORI KONDO, YUKI NEMOTO, YUKI KOBARI, HIROKI ISHIHARA, HIDEKAZU TACHIBANA, KAZUHIKO YOSHIDA, YASUNOBU HASHIMOTO, TOSHIO TAKAGI, JUNPEI IIZUKA and KAZUNARI TANABE
Anticancer Research March 2021, 41 (3) 1607-1614; DOI: https://doi.org/10.21873/anticanres.14922
YUDAI ISHIYAMA
1Department of Urology, Tokyo Women’s Medical University Medical Center East, Tokyo, Japan;
2Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TSUNENORI KONDO
1Department of Urology, Tokyo Women’s Medical University Medical Center East, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tsunenori.kondo{at}twmu.ac.jp
YUKI NEMOTO
2Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan;
3Department of Urology, Saiseikai Kawaguchi General Hospital, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUKI KOBARI
2Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROKI ISHIHARA
2Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDEKAZU TACHIBANA
1Department of Urology, Tokyo Women’s Medical University Medical Center East, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUHIKO YOSHIDA
2Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YASUNOBU HASHIMOTO
3Department of Urology, Saiseikai Kawaguchi General Hospital, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOSHIO TAKAGI
2Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JUNPEI IIZUKA
2Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUNARI TANABE
2Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 41 no. 3 1607-1614
DOI 
https://doi.org/10.21873/anticanres.14922
PMID 
33788756

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received February 3, 2021
  • Revision received February 16, 2021
  • Accepted February 17, 2021
  • Published online March 3, 2021.

Copyright & Usage 
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Author Information

  1. YUDAI ISHIYAMA1,2,
  2. TSUNENORI KONDO1⇑,
  3. YUKI NEMOTO2,3,
  4. YUKI KOBARI2,
  5. HIROKI ISHIHARA2,
  6. HIDEKAZU TACHIBANA1,
  7. KAZUHIKO YOSHIDA2,
  8. YASUNOBU HASHIMOTO3,
  9. TOSHIO TAKAGI2,
  10. JUNPEI IIZUKA2 and
  11. KAZUNARI TANABE2
  1. 1Department of Urology, Tokyo Women’s Medical University Medical Center East, Tokyo, Japan;
  2. 2Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan;
  3. 3Department of Urology, Saiseikai Kawaguchi General Hospital, Saitama, Japan
  1. Correspondence to: Tsunenori Kondo, Department of Urology, Tokyo Women’s Medical University Medical Center East, 2-1-10 Nishiogu, Arakawa-ku, Tokyo, 116-8567 Japan. Tel: +81 338108111, Fax: +81 338100705, e-mail: tsunenori.kondo{at}twmu.ac.jp
View Full Text

Statistics from Altmetric.com

Cited By...

  • 22 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 41, Issue 3
March 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Predictive Impact of Prognostic Nutritional Index on Pembrolizumab for Metastatic Urothelial Carcinoma Resistant to Platinum-based Chemotherapy
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
20 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Predictive Impact of Prognostic Nutritional Index on Pembrolizumab for Metastatic Urothelial Carcinoma Resistant to Platinum-based Chemotherapy
YUDAI ISHIYAMA, TSUNENORI KONDO, YUKI NEMOTO, YUKI KOBARI, HIROKI ISHIHARA, HIDEKAZU TACHIBANA, KAZUHIKO YOSHIDA, YASUNOBU HASHIMOTO, TOSHIO TAKAGI, JUNPEI IIZUKA, KAZUNARI TANABE
Anticancer Research Mar 2021, 41 (3) 1607-1614; DOI: 10.21873/anticanres.14922

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Predictive Impact of Prognostic Nutritional Index on Pembrolizumab for Metastatic Urothelial Carcinoma Resistant to Platinum-based Chemotherapy
YUDAI ISHIYAMA, TSUNENORI KONDO, YUKI NEMOTO, YUKI KOBARI, HIROKI ISHIHARA, HIDEKAZU TACHIBANA, KAZUHIKO YOSHIDA, YASUNOBU HASHIMOTO, TOSHIO TAKAGI, JUNPEI IIZUKA, KAZUNARI TANABE
Anticancer Research Mar 2021, 41 (3) 1607-1614; DOI: 10.21873/anticanres.14922
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • C-reactive Protein Is a Prognostic Factor for Survival in Metastatic Upper Tract Urothelial Carcinoma Patients Receiving Pembrolizumab
  • Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab
  • The Modified Glasgow Prognostic Score and Prognostic Nutritional Index as Prognostic Markers in Patients With Metastatic Breast Cancer Treated With Eribulin
  • Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma
  • Impact of C-reactive Protein Flare Response in Patients With Advanced Urothelial Carcinoma Who Received Pembrolizumab
  • Google Scholar

More in this TOC Section

  • Comparison of RATS Lobectomy and VATS Lobectomy for Early-stage Non-small Cell Lung Cancer
  • Effectiveness of Chemotherapy With/Without Radiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Population-based Target Trial Emulation Study
  • Genomic Profiling of Cancerous Areas, Dysplasia, and Background Mucosa in Ulcerative Colitis-associated Colorectal Cancer
Show more Clinical Studies

Keywords

  • immunotherapy
  • Urothelial carcinoma
  • nutritional status
  • pembrolizumab
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire